SUMMARY The minimal inhibitory concentration of azlocillin for Pseudomonas aeruginosa is appreciably reduced when combined with the mucolytic agent mesna (Mistabron) because of an independent bacteriostatic effect of mesna. 
In vitro assessment of combined antibiotic and mucolytic treatment 825 centration of mesna was combined with azlocillin. We then tested the effect of mesna alone and found that it inhibited the growth of all strains of Ps. aeruginosa, both matt and mucoid types, at a concentration of 1 % and greater. Mistabron alone has been clinically shown to improve the chronic sputum production of cystic fibrosis patients.' As many of these patients have chronic pseudomonas lung infections both the antipseudomonal and mucolytic actions of mesna may be of benefit. Further studies are required to look at the antipseudomonal effect of mesna in vivo as this drug used alone or combined with azlocillin may have an important role in the treatment of chronic pseudomonal lung infection.
SUMMARY In a study of 6 children with cystic fibrosis receiving intravenous antibiotics for pseudomonas lung infection, serum endotoxin values were monitored by a modification of the limulus lysate technique. The values fell with treatment, reflecting a response that was not always apparent on clinical assessment. Endotoxin concentrations may offer a more precise way of monitoring the effects of antibiotic treatment in CF patients.
As the respiratory tract of children with cystic fibrosis (CF) becomes colonised with Pseudomonas aeruginosa there is usually an associated clinical deterioration. It is because of this association that attempts are often made to control Ps. aeruginosa infection by courses of intravenous antibiotics, although it is questionable whether their effect is valuable or prolonged.' It is difficult, using routine bacteriological methods, to assess the true extent of the infection since quantitative sputum bacteriology is imprecise. Moreover, the extent of lung damage produced by Ps. aeruginosa and the effect of antibacterial treatment can only be assessed indirectly.
All Gram negative organisms produce endotoxin, a part of their cell wall. It is a high molecular weight complex of lipid, polysaccharide, and protein2 and the bioactive part of the molecule is remarkably conserved among most Gram negative organisms. This means that the biological effects of endotoxin from most of these organisms are very similar despite species differences.
We have developed a rapid, sensitive assay for endotoxin which depends upon its biological activity, and wished to see whether endotoxin was detectable in the serum of patients with exacerbation of CF, and if so, whether the value changed in response to treatment. Patients and methods As part of a wider study of bacterial antigenaemia in CF, 6 children with CF (four girls and two boys) with ages ranging from 6-19 years were studied. They were admitted to hospital for antibiotic treatment either for an acute exacerbation or in an attempt to improve respiratory function before a new school term. They received their usual diet and physiotherapy. Antibiotic treatment consisted of gentamycin (3 mg/kg/8 hourly, IV) and carbenicillin (50 mg/kg/8 hourly, IV) for 10-14 days.
A clinical scoring system, grading symptoms 0-3 for cough, shortness of breath, and sputum production was devised. Peak expiratory flow rate was measured daily and the growth of Ps. aeruginosa from sputum was classed as absent, light, moderate, or heavy.
Blood for endotoxin assay was taken with routine specimens before treatment, after 5-7 days treatment, and where possible after completion of the antibiotic course. Specimens were collected by clean venepuncture into endotoxin free glass bijou bottles, allowed to clot at room temperature, and separated within one hour. Serum was then stored at -20°C until assayed.
The assay3 was a modification of the limulus assay, using the chromogenic substrate S2222 (Kabi Diagnostics 
